High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates.
de Goeij, Bart E C G; Satijn, David; Freitag, Claudia M; Wubbolts, Richard; Bleeker, Wim K; Khasanov, Alisher; Zhu, Tong; Chen, Gary; Miao, David; van Berkel, Patrick H C; Parren, Paul W H I.
Mol Cancer Ther
; 14(5): 1130-40, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25724665
Chemically generated IgG2 bispecific antibodies through disulfide bridging.
Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting.
Magnetic resonance imaging of tumor with a self-traceable polymer conjugated with an antibody fragment.
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation.
Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
Second-line chemotherapy for patients with advanced gastric cancer.
<sup>64</sup>Cu-Labeled Trastuzumab Fab-PEG<sub>24</sub>-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.